Chronic high-fat diet induces multi-organ dysfunction and metabolic homeostasis disruption in Macaca fascicularis

Abstract

Background: The aim of the study was to develop a non-human primate model of metabolic dysfunction in Macaca fascicularis using chronic high-fat diet (HFD) to mimic clinical disease progression.

Methods: Thirty-five male macaques aged 10–15 years underwent an 18-month HFD intervention. Physiological parameters (BMI, BP, hematology), liver fat fraction (evaluated by ultrasound/MRI), cardiac function (assessed by echocardiography), and histopathology (using liver biopsy) were measured before and after the intervention. Serum proteomics with KEGG/STRING analyses identified molecular mechanisms.

Results: Within 6 months, HFD induced dyslipidemia (elevated TG, TCHO, HDL-C, LDL-C). After 18 months, metabolic dysfunction-associated steatohepatitis (MASH) was confirmed by histopathology in 57.14% (16/28) of macaques, diabetes (elevated FPG/HbA1c) in 17.86% (5/28), and myocardial hypertrophy (elevated LVMass/LAD) in 46.43% (13/28). Proteomics identified Bile acid-CoA: amino acid N-acyltransferase (BAAT) as a MASH hallmark protein, the level of which was inversely correlated with the degree of fibrosis. For diabetes, citrate synthase (CS) and malate dehydrogenase 1 (MDH1) impaired glucose oxidation via the TCA cycle, while hexose-6-phosphate dehydrogenase (H6PD) disrupted gluconeogenesis. Myocardial hypertrophy was associated with the downregulation of SRC proto-oncogene, non-receptor tyrosine kinase (SRC), mitogen-activated protein kinase 14 (MAPK14), emerin (EMD), and integrin subunit beta 1 (ITGB1).

Conclusions: An 18-month HFD successfully established a translational M. fascicularis model replicating key metabolic disorders (MASH, diabetes, cardiac hypertrophy). BAAT, CS/MDH1/H6PD, and SRC/MAPK14/EMD/ITGB1 were identified as mechanistic biomarkers for these conditions.

Keywords

animal model / Macaca fascicularis / metabolic dysfunction / proteome

References

[1] Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008; 29(7): 777-822.

[2] Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018; 20(2): 12.

[3] Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes. 2007; 31(1): 177-188.

[4] Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Nutrition. 1988; 13(1): 65.

[5] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285(19): 2486-2497.

[6] Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010; 375(9710): 181-183.

[7] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus Statement from the international diabetes federation. Diabet Med. 2006; 23(5): 469-480.

[8] Harwood HJ, Listrani P, Wagner JD. Nonhuman primates and other animal models in diabetes research. J Diabetes Sci Technol. 2012; 6(3): 503-514.

[9] Lutz TA, Woods SC. Overview of animal models of obesity. Curr Protoc Pharmacol. 2012; 5:Unit5.61.

[10] Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin. 2012; 33(2): 173-181.

[11] Ito M, Suzuki J, Tsujioka S, et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res. 2007; 37(1): 50-57.

[12] Panchal SK, Poudyal H, Iyer A, et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol. 2011; 57(5): 611-624.

[13] Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol. 2014; 34(6): 726-732.

[14] Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes Rev. 2014; 10(2): 131-145.

[15] Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007; 125(3): 451-472.

[16] Enriquez JR, McCauley HA, Zhang KX, et al. A dietary change to a high-fat diet initiates a rapid adaptation of the intestine. Cell Rep. 2022; 41(7):111641.

[17] Afonso-Oramas D, Santana-Cordón L, Lemus-Mesa A, et al. Drastic decline in vasoactive intestinal peptide expression in the suprachiasmatic nucleus in obese mice on a long-term high-fat diet. Brain Res Bull. 2023; 202:110756.

[18] Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023; 29(3): 562-573.

[19] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4): 1335-1347.

[20] Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023; 8(10): 943-954.

[21] Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024; 154:155835.

[22] Nakamura T, Fujiwara K, Saitou M, Tsukiyama T. Non-human primates as a model for human development. Stem Cell Reports. 2021; 16(5): 1093-1103.

[23] Gao S, Li F, Zha S. High-fat diet induced cynomolgus monkey model of non-alcoholic fatty liver disease. Lab Anim Comp Med. 2020; 40(2): 123.

[24] Camacho RC, Polidori D, Chen T, et al. Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions. Diabetes Obes Metab. 2023; 25(4): 1068-1079.

[25] Wang H, Tan T, Wang J, et al. Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis. Sci Rep. 2015; 5:15019.

[26] Liu Y, Gu H, Wang H, et al. Hepatic steatosis and fibrosis in obese, dysmetabolic and diabetic nonhuman primates quantified by noninvasive echography. J Diabetes Metab. 2017; 8(10): 1-9.

[27] Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007; 11(1): 1-16.

[28] Kullmann S, Wagner L, Hauffe R, et al. A short-term, high-caloric diet has prolonged effects on brain insulin action in men. Nat Metab. 2025; 7(3): 469-477.

[29] Yang Y, Lu X, Liu N, et al. Metformin decelerates aging clock in male monkeys. Cell. 2024; 187(22): 6358-6378.e29.

[30] Chen C, Li H, Song J, et al. Role of apolipoprotein A1 in PPAR signaling pathway for nonalcoholic fatty liver disease. PPAR Res. 2022; 2022:4709300.

[31] Zhao Y. Association between apolipoprotein B/A1 and the risk of metabolic dysfunction associated fatty liver disease according to different lipid profiles in a Chinese population: a cross-sectional study. Clin Chim Acta. 2022; 534: 138-145.

[32] Liu Y, Wu H, Wang Z, et al. Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide. Clin Res Hepatol Gastroenterol. 2021; 45(2):101312.

[33] Alrehaili BD, Lee M, Takahashi S, Gonzalez FJ, Lee Y. Mice with bile acid-CoA: amino acid N-acyltransferase deletion are protected from obesity. FASEB J. 2020; 34: 1.

[34] Xu C, Li H, Tang CK. Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: pathophysiology, molecular biology, and potential clinical implications. Metabolism. 2022; 131:155180.

[35] Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019; 1(4): 312-328.

[36] Amarapurka DN, Amarapurkar AD, Patel ND, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol. 2006; 5(1): 30-33.

[37] Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017; 14(1): 32-42.

[38] Neeland IJ, Lim S, Tchernof A, et al. Metabolic syndrome. Nat Rev Dis Primers. 2024; 10(1):77.

[39] Burkart AM, Tan K, Warren L, et al. Insulin resistance in human iPS cells reduces mitochondrial size and function. Sci Rep. 2016; 6:22788.

[40] Alhindi Y, Vaanholt LM, Al-Tarrah M, et al. Low citrate synthase activity is associated with glucose intolerance and lipotoxicity. J Nutr Metab. 2019; 2019:8594825.

[41] Jungtrakoon Thamtarana P, Marucci A, Pannone L, et al. Gain of function of malate dehydrogenase 2 and familial hyperglycemia. J Clin Endocrinol Metab. 2022; 107(3): 668-684.

[42] Magori E, Nakamura M, Inoue A, et al. Malate dehydrogenase activities are lower in some types of peripheral leucocytes of dogs and cats with type 1 diabetes mellitus. Res Vet Sci. 2005; 78(1): 39-44.

[43] Uçkaya G, Karadurmuş N, Kutlu O, et al. Adipose tissue 11-beta-hydroxysteroid dehydrogenase type 1 and Hexose-6-phosphate dehydrogenase gene expressions are increased in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008; 82(2): S135-S140.

[44] Soongsathitanon J, Umsa-Ard W, Thongboonkerd V. Proteomic analysis of peripheral blood polymorphonuclear cells (PBMCs) reveals alteration of neutrophil extracellular trap (NET) components in uncontrolled diabetes. Mol Cell Biochem. 2019; 461(1–2): 1-14.

[45] Liu S, Zhang Y, Xie X, et al. Application of two-dimensional electrophoresis in the research of retinal proteins of diabetic rat. Cell Mol Immunol. 2007; 4(1): 65-70.

[46] Cao Y, Sun Y, Zou S, Li M, Xu X. Orally administered Baker's yeast β-glucan promotes glucose and lipid homeostasis in the livers of obesity and diabetes model mice. J Agric Food Chem. 2017; 65(44): 9665-9674.

[47] Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity (Silver Spring). 2017; 25(8): 1313-1316.

[48] Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021; 22(21):11629.

[49] Wang Z, Li L, Zhao H, Peng S, Zuo Z. Chronic high fat diet induces cardiac hypertrophy and fibrosis in mice. Metabolism. 2015; 64(8): 917-925.

[50] Zheng S, Tan W, Li X, et al. Aged monkeys fed a high-fat/high-sugar diet recapitulate metabolic disorders and cardiac contractile dysfunction. J Cardiovasc Transl Res. 2021; 14(5): 799-815.

[51] Jiang S, Huang C, Wang S, et al. Network pharmacology-based strategy for predicting therapy targets of citri reticulatae pericarpium on myocardial hypertrophy. Biomed Res Int. 2022; 2022:4293265.

[52] Liu Y, Li Q, Shao C, et al. Exploring the potential mechanisms of guanxinshutong capsules in treating pathological cardiac hypertrophy based on network pharmacology, computer-aided drug design, and animal experiments. ACS Omega. 2024; 9(16): 18083-18098.

[53] Marin TM, Clemente CF, Santos AM, et al. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways. Circ Res. 2008; 103(8): 813-824.

[54] Zhou W, Liu W, Zhou D, Li A. ITGB1 suppresses autophagy through inhibiting the mTORC2/AKT signaling pathway in H9C2 cells. Pharmazie. 2022; 77(5): 137-140.

[55] Yang L, Li Y, Wang X, et al. Overexpression of miR-223 tips the balance of pro- and anti-hypertrophic signaling cascades toward physiologic cardiac hypertrophy. J Biol Chem. 2016; 291(30): 15700-15713.

[56] Frey UH, Lieb W, Erdmann J, et al. Characterization of the GNAQ promoter and association of increased Gq expression with cardiac hypertrophy in humans. Eur Heart J. 2008; 29(7): 888-897.

[57] Tu M, Miyamoto S. RHOA, a small G-protein, signals to mitophagy through regulation of PINK1 protein stability and protects cardiomyocytes against ischemia. Autophagy. 2023; 19(6): 1865-1866.

[58] Shimojima M, Yuasa S, Motoda C, et al. Emerin plays a crucial role in nuclear invagination and in the nuclear calcium transient. Sci Rep. 2017; 7:44312.

[59] Yamagishi K, Aleksic N, Hannan PJ, Folsom AR, ARIC Study Inverstigators. Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. J Atheroscler Thromb. 2010; 17(4): 402-409.

[60] Chinnaraj M, Planer W, Pozzi N. Structure of coagulation factor II: molecular mechanism of thrombin generation and development of next-generation anticoagulants. Front Med (Lausanne). 2018; 5:281.

[61] Wu L, Xiang B, Zhang H, et al. Three novel recessive mutations in LAMA2, SYNE1, and TTN are identified in a single case with congenital muscular dystrophy. Neuromuscul Disord. 2017; 27(11): 1018-1022.

[62] Nurden AT. Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses? Blood Rev. 2017; 31(5): 287-299.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.